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Direct to consumer (DTC) advertising of pharmaceutical drugs is often cited as the culprit for 
inflated patient demand for advertised drugs
1,2
. Alternate to this economic concern, we provide 
an evidenced based psychological account of another concern that warrants the re-examination of 
the merits of DTC advertising of prescription drugs. Across six experiments and a sample of 
3,059 US participants, we find reliable evidence for the argument dilution effect. Specifically, 
when commercials list severe side-effects along with the most frequent, which includes both 
serious and minor, as required by the FDA, it dilutes consumers’ judgements of the overall 
severity of side effects, compared to when only the serious side-effects are listed. Furthermore, 
consumers’ reduced judgment of severity leads to greater attraction to those drugs. In regulating 
pharmaceutical advertisements, the FDA appear to have paradoxically dampened consumers’ 
judgements of overall severity and risk, and increased the marketability of these drugs.   
 Unique to only the US and New Zealand, direct to consumer (DTC) advertising of 
pharmaceutical drugs is a $4.5 Billion a year industry
3
. The Food and Drug Administration 
(FDA), in promoting the interests of consumers (and patients), regulated and provided guidelines 
to pharmaceutical companies for both print and media advertising. The nexus of these guidelines 
stipulated a fair balance between benefits and risk information – the space allotted on print media 
and airtime on broadcast media, to side effects needed to sufficiently inform consumers of the 
various side-effects and precautions, in addition to the standard marketing of the drug’s benefits. 
The ubiquitous 60 second television commercials, where significant portions of the latter part of 
the advertisement is devoted to a laundry list of side effects, owes its impetus to the FDA 
regulations of 1997/1999
4–6
. Although the medical community, the general populous, and media 
have expressed their annoyance and ridicule for these advertisements
1,2
, we contend there exists 
a meaningful concern and downstream negative consequences of these regulated advertisements. 
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Specifically, despite FDA’s well intentions to inform (vulnerable) consumers of the potential risk 
and side-effects of pharmaceutical drugs, these regulated advertisements, we contend, might 
have over the years produced the unintended outcome of dampening one’s assessment of side-
effects and in the process further promoted the benefits and attractiveness of the drug.  
From the decision making literature we know that individuals are plagued by a series of 
biases
7
, resulting in suboptimal decisions and outcomes. One of these established biases is the 
argument dilution effect
8,9
. When making predictions about a target, a person evaluates an array 
of information – both diagnostic and non-diagnostic to the evaluation. The dilution effect occurs 
whereby those who assess the mixed set of diagnostic and non-diagnostic information arrive at 
less extreme predictions in comparison to those who assessed only diagnostic information. That 
is, the non-diagnostic information – information of little value and consequence for outcome 
prediction – dilutes the value and importance of the diagnostic information in our 
prognostication. The dilution effect is evidenced in various social and non-social judgements, 
ranging from assessing intellectual ability
10
, guilt of a suspect on trial
9
, consumer brands
11
 and 
lottery judgements
12
.  
The most robust psychological explanation is based on an averaging effect
13,
. In this 
model, each point of information is afforded a weighted score, whereby adding equal weights to 
non-relevant information as those assigned to relevant information, dilutes people’s overall 
judgement. Further, this model has been shown to predict both social and non-social 
judgments
13,14
. We therefore contend the averaging effect and consequently the dilution of a 
category extends also to relevant but weak arguments, whereby a mixed set of information that 
contains both strong and weak relevant information dilutes people’s overall judgement of the 
argument. Alternate to the extant work highlighting the cognitive and affective information that 
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produce information distortion in DTC advertisements
15,16
, we contend the FDA in regulating 
DTC advertisements to list side-effects, that range from the serious – such as stroke, and 
thoughts of suicide – to those less serious, such as dry mouth and headache, have diluted 
consumers’ judgements of overall severity of the drug’s side-effects. Thus, the current practice 
of listing both severe and frequent but minor side-effects, paradoxically down-plays the risk 
factors in assessing the suitability of the drug, and in turn increases its attractiveness.            
We conducted six experiments to test whether providing information of minor side 
effects along with major side effects reduces overall perception of severity of side effects 
associated with the drug. In doing so, our research makes three important contributions. First, 
extant work on argument dilution has centered on irrelevant (non-diagnostic) information 
towards the dilution of attribute judgment. We extend this by demonstrating that relevant 
diagnostic, but weak information also influences our calculus of argument strength. In addition, 
the dilution effect has primarily concentrated on positive information; we further the reach of the 
argument dilution effect by documenting it in the assessment of negative attributes. Finally, and 
most importantly, the applied results hold important policy implications in communicating risk 
to consumers of pharmaceutical drugs.  
As an initial test of our hypothesis in Study 1, we recruited 804 US participants from an 
online national database. Participants listened to a real drug commercial of Cymbalta – a 
depression drug marketed DTC in the US – and judged the severity of its side effects. Half the 
participants listened to the entire 78 seconds of the audio commercial (full audio condition), 
whereas the other half listened to a slightly shorter 75 seconds version (partial audio condition), 
absent of three minor side-effects (stimulus material used for this and other studies is available at 
the open science framework link provided at the end of the article). This manipulation 
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constituted an omission of less than 4% of the advertisement’s content. Following this, 
participants in both full and partial audio conditions, rated severity of the drug’s side effects and 
its attractiveness.  
As hypothesized, participants who heard the commercial in entirety, rated the drug as 
containing less severe side effects than participants who heard the three second shorter 
commercial with no mention of minor side effects (F(1,802)=5.52, p=.019, d=.17), suggesting 
that minor side effects diluted the perception of overall severity of side effects associated with 
Cymbalta (Table 1 and 2). We did not find a significant effect of our manipulation on drug 
attractiveness but an indirect effect of dilution was observed, such that as participants evaluated 
the side effects to be less severe, the drug was rated as more attractive in the full audio condition 
compared to the partial audio condition (b=.06, p=.019, 95%CI [.01, .11]). As demonstrated in 
past work, an indirect effect is sufficient to demonstrate mediation, as lack of direct effect on the 
dependent variable can be an indication of other variables suppressing the effect of an 
independent variable
17,18
. Additionally, to rule out lack of attention as an alternate explanation 
for our results, we asked participants to recall all major side effects that were reported in the 
audio commercial. Participants correctly remembered more number of major side effects in the 
full audio condition than in the partial audio condition (MFull = 3.18, MPartial =2.78, 
F(1,802)=51.12, p<.001).  
If the psychological process of dilution is the underlying mechanism driving our results, 
then participants who recalled more number of side effects in the major side effects condition, 
should report the drug to be overall more severe compared to those who recalled less number of 
major side effects. Accordingly, we tested for an interaction effect of the manipulation and recall 
of major side effects on the drug’s overall severity. Analysis revealed that the main effect of 
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condition on drug severity became marginal but was in the right direction (F(1,800)=3.38, 
p=.095), and there was a main effect of recall such that higher recall lead to greater drug severity 
(F(1,800)=15.94, p<.001). However, most importantly, a significant interaction between 
condition and recall was observed (F(1,800)=7.03, p=.008).  Upon decomposing the interaction 
(see Figure 1), we find the slope for participants in the partial (major side effects only) condition 
was positive and significant (b=.48, p<.001) such that participants rated the drug to be more 
severe when they were able to recall more number of side effects compared to when they 
recalled fewer side effects. The slope for participants in the full (major and minor side effects) 
condition was not significant (b=.05, p=.66), implying that recalling more number of side effects 
did not increase ratings of drug severity as their evaluations were ostensibly diluted by the 
presence of minor side effects. This analysis provides initial evidence of argument dilution as the 
underlying process driving the effect and importantly strong evidence ruling out attention as an 
alternate explanation of our results as with better recall in the full advertisement condition, the 
presence of minor side effects significantly diluted participant’s severity judgments. Finally, our 
results remain consistent when controlling for participant’s symptoms for depression (p=.021)  
and perceptions of trade-off (p=.063). The results from Study 1 are important in documenting the 
presence of this phenomenon using a real-world DTC commercial with very minimal change in 
manipulation. 
To establish both the robustness of this effect and further increase the ecological validity 
of our research, in Studies 2a-c we replicated the effects using a different medium – print – and 
also varied the architecture of these print advertisements. According to the FDA guidelines, print 
advertisement apart from promoting the drug should also highlight its various side effects, but 
this information is generally buried with other information in smaller text and often in an 
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inconspicuous location within the advertisement. We reasoned that changing a couple of side 
effects within a torrent of information would provide a more conservative test of our hypotheses.  
Accordingly, in Study 2a, participants were shown an actual print advertisement for the drug 
Lunesta, designed to treat sleep disorder. Randomly assigned participants either read the 
complete set of 4 side effects (2 major and 2 minor) – complete side effects condition (n=200) – 
or a subset of 2 major side effects – major side effects condition (n=200). As hypothesized, a 
one-way ANOVA revealed that participants who read all 4 side effects evaluated the drug as 
containing less severe side effects than those who read just the 2 major side effects 
(F(1,398)=6.43, p=.012, d=.25, Table 1). Similar to Study 1, we did not observe direct effect on 
drug attractiveness but an indirect effect of dilution was observed, such that as participants 
evaluated the side effects to be lower in severity, the drug was rated more attractive in the 
complete side effects (both major and minor) condition compared to the major side effects only 
condition (b=.10, p=.012, 95%CI [.02, .18]). Further, as expected and similar to Study 1, our 
results remain consistent when controlling for susceptibility to sleep disorder (p=.012) and 
tradeoff (p=.053).  
In Study 2b, we presented participants with an alternate and further conservative 
presentation of the merits and side-effects of another actual prescription drug for depression, 
Abilify, via a Drug Facts Box. Drug Facts Box is a one page summary that includes benefits and 
harmful effects of a drug and shown to improve consumer decision-making when choosing 
prescription drugs
19,20
. Participants were randomly assigned to a complete (n=196) or major 
information condition (n=203). In the complete information condition participants read 
information of the benefits and both the major and minor side effects of the drug, whereas in the 
major side effects condition, information about minor side effects was removed from the Drug 
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Facts Box. Participants then responded to measures identical to Study 1 and 2a. A one-way 
ANOVA revealed significant difference across the two condition (F(1,397)=13.90, p<.001, 
d=.37), such that participants in the complete information condition rated the drug lower on 
severity (M=5.33, SD=1.22) compared to those in the major side effects only condition (M=5.74, 
SD=.98). Consistent with Study 1 and Study 2a, we also found indirect effect of the manipulation 
on drug attractiveness such that participants evaluated the drug as more attractive in the complete 
information condition compared to the major side effects only condition due to their lower 
judgment of the drug’s severity of side effects (b=.14, p<.001, 95%CI [.07,.22]).   
In Study 2c, to further demonstrate the robustness of our effects, we employed another 
version of a drug commercial. Specifically, participants were presented with content for another 
actual direct to consumer drug, Concerta - prescribed to treat attention deficit hyperactive 
disorder. We formatted the advertisement such that information about the side effects was 
sandwiched in between statements highlighting the benefits and merits of the drug. This followed 
the architecture of the audio commercial (Study 1), where side effects were presented amongst 
its benefits, but unlike Study 1, the side effects were more precisely and squarely sandwiched 
between the merits of the drug. Similar to the other studies, participants were randomly assigned 
to a complete side effects (n=225) or major side effects only condition (n=227). Additionally, to 
rule out any potential measurement bias in participant’s ratings of drug severity, in contrast to the 
previous studies, participants responded to an additional measure of drug severity – how safe it 
would be to consume that drug (reverse coded).  In addition to being an extra measure, we also 
ensured the question was framed in a more positive direction focused on safety, rather than harm. 
Replicating our findings from before, a one way ANOVA revealed a significant effect 
(F(1,450)=10.25, p=.002, d=.30) such that participants judged the drug less severe in the 
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complete information condition (M=5.13, SD=1.16) compared to those in the major side effects 
only condition (M=5.47, SD=1.10). Bootstrap analysis revealed a significant indirect effect of 
our manipulation on drug attractiveness such that lower perception of drug’s severity in the 
complete information condition as opposed to major side effects only condition made the drug 
appear more attractive (b=.14, p=.001, 95%CI [.06,.23]). Our results also remained consistent 
when controlling for participant’s susceptibility to the disease (p=.002) and their perceptions of 
trade-off (p=.003).        
Together with the audio commercial in Study 1, the print advertisements of Study 2a, 2b 
and 2c, by utilizing different drugs, different architecture in presenting information, and different 
measures of severity ratings, we find strong and consistent support of dilution in DTC 
pharmaceutical commercials
1
. Furthermore, we ran a separate study where weak side-effects 
were presented before (primacy) or after (recency) the strong side-effects (Mbefore=5.62, 
Mafter=5.72, F(1,198)=0.50, p=.48), thereby ruling out recency effect as an alternate account of 
our prior findings
21
. Thus, listing all frequent side effects, both major and minors, does not 
dampen the drug’s attractiveness, but paradoxically increase it.    
Having demonstrated the phenomenon using an audio commercial and replicated the 
effects with multiple print advertisements, in Study 3 we set out to further establish the 
robustness of this phenomenon by experimentally attenuating
22
 the cognitive process  of dilution 
(i.e., an averaging effect) – the psychological process we argue is the engine behind our observed 
set of results. If dilution is the result of averaging all side effects listed, it is plausible the process 
is dampened if participants can cognitively isolate major and minor side effects, by assigning 
greater emphasis/weight to major and less emphasis/weight to minor side effects when 
evaluating the overall severity of side effects. Accordingly, we added a third condition – 
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complete-major side effects emphasized condition, wherein all side effects were presented but 
major side effects were presented in bold 14 point red text and minor side effects presented in 
regular 12 point black text. Thus, drawing greater emphasis to major side effects should result in 
the mental separation and the assignment of greater weights to the major side effects when 
cognitively computing the overall severity of side effects.  
A one-way ANOVA with severity of side effects as the dependent variable resulted in a 
significant main effect across the three experimental conditions (F(2,601)=7.56, p<.001). As 
predicted, there was no difference in means between the major side effect condition and the 
complete-major side effects emphasized condition (t(401) = .11, p = .91, Table 1). Consistent 
with Study 1 and Study 2a-c, participants in the complete side effects condition perceived the 
drug to be less severe in side-effects than those assigned to the major side effects condition 
(t(398)=3.28, p=.001), d=.33, Table 1). However, more importantly we also found that 
participants rated side effects to be significantly more severe in the complete-major side effects 
emphasized condition than in the complete side effects condition (t(403)=3.20, p=.002, d=.32, 
Table 1). Thus, by experimentally moderating the cognitive process of averaging, we further 
provide evidence of argument dilution as the psychological process, driving the varied 
assessment of severity. Finally, consistent with previous studies, we did not observe direct effect 
on drug attractiveness but controlling for complete side effects condition, a significant negative 
indirect effect was observed for major side effects condition (b=-.11, p=.001, 95%CI [-.18, -.05]) 
and complete major side effects emphasized condition (b=-.11, p=.002, 95%CI [-.17, -.04]) on 
drug attractiveness via severity perceptions. Specifically, as participants in the complete side 
effects condition rated the side effects to be lower in severity they found it to be more attractive 
compared to those participants in the major side effects condition and complete major side 
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effects emphasized condition. Finally, our results remain identical when controlling for 
symptoms of sleep disorder (p=.001) and trade-off (p=.001).  
Thus, by experimentally moderating the psychological process we contend is driving the 
observed phenomenon, Study 3 replicates the findings of Study 1 and Studies 2a-c, and most 
importantly further extends our results by experimentally demonstrating the psychological 
process-underlying phenomenon of argument dilution effect. Furthermore, Study 3 provides an 
initial practical avenue through which dilution can be tempered in DTC advertising.  
Specifically, by listing both major and minor side effects, but nudging consumers’ attention and 
weight allocated to the major side effects, consumers appear less susceptible to the argument 
dilution bias.  
Finally, to empirically demonstrate the robustness of our effect we conducted a meta-
analysis of the above five studies and also Study S1 in the supplementary information 
(N=2,855).  Complete side effects emphasized condition in Study 3 was not included in the 
meta-analysis, as that was used to test the psychological process via moderation. However, the 
other two conditions were included in the meta-analysis.  Using random effects analysis and 
found the effect to be significant with 95% confidence intervals not containing zero (d=.285, 
95%CI [.203, .366]). Thus, paradoxically, listing both major and minor side effects appears to 
help the marketability of the drug. 
Recently, the American Medical Association’s House of Delegates called for a ban on 
DTC advertising in the US
23
, citing these advertisements produce an inflated demand for drugs.  
In addition to the theoretical contribution of demonstrating the psychological process of dilution 
among negatively valenced arguments, importantly we provide, an evidenced based 
psychologically grounded account of a more serious concern that warrants the re-examination of 
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the merits of DTC advertising of prescription drugs. Specifically, across a sample of 3,059 US 
participants, the target audience for these commercials, we find strong support for the 
psychological dilution of severity in judgments of side effects, when both major and minor side-
effects are presented. Further, because of these diluted severity judgements, drug advertisements 
containing all side-effects are judged to be more attractive. More broadly, this raises an ethical 
dilemma - a conflict between what could be viewed as a moral imperative to provide complete 
information to the patient versus a form of paternalism that attempts to influence the patient’s 
decisions in a manner that makes them better off 
24
. The choice architecture employed in Study 
3, which affords consumers the ability to compartmentalize and assign appropriate weights to 
major vs. minor side effects, presents one possible avenue by which pharmaceutical companies 
and regulators may look to attenuate the argument dilution effect, while maintaining 
transparency. Whichever nudge is implemented to combat this bias, it is clear our results 
underscore the unintended consequences of current advertisements, and the need for the FDA to 
reassess the prescriptive policy requirement for pharmaceuticals companies to list the full range 
of side effects in DTC drug commercials. 
Methods 
Ethics Statement.  The ethics approval for this project was provided by London Business 
School as per the school’s guidelines. In line with ethical guidelines, all participants provided 
informed consent before taking the studies.  
Study 1. Participants. Eight hundred and four participants from the Unites States - the target 
audience of DTC advertisements - were recruited through Amazon Mechanical Turk (AMT) 
(Mage=35.72; 48.26% female; response rate 87.7%). Given the subtle manipulation, we collected 
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a large sample (≈400 per cell) to detect smaller effects while ensuring we minimized the 
probability of Type-1 error. 
Design and Procedure. Participants were instructed to listen and judge the severity of side 
effects of an actual drug commercial for Cymbalta – a depression drug marketed DTC in the US. 
Participants were randomly assigned to either a full 78-seconds condition (full audio condition) – 
where they listened to the complete advertisement for Cymbalta, or to a partial 75-seconds 
condition (partial audio condition), that did not include the mention of three minor side effects 
(nausea, dry mouth and constipation). This manipulation constituted an omission of less than 4% 
of the advertisement’s content. Following this, participants in both full and partial audio 
conditions, rated severity of the drug’s side effects by answering two questions – how 
serious/harmful are Cymbalta’s side effects – on a Likert scale, from 1 (definitely not 
serious/harmful) to 7 (definitely serious/harmful). Participants also judged attractiveness of the 
drug on a 7 point Likert scale by answering: 1) if you were in the market for a depression drug, 
how likely would you purchase Cymbalta, 2) how effective would Cymbalta be in curing 
depression and by answering 3) at what percentage price, above or below, the average market 
price of other depression drugs should Cymbalta be priced, on a slider scale ranging from -50 to 
+50. The composite was created by combining z scores for the three measures (=.70). 
 We controlled for participants suffering from depression or similar symptoms, as these 
participants could be motivated to ignore or downplay the severity of the drug’s side effects. 
Participants thus responded to one item measure on a 7-point scale – “Please indicate how often 
you suffer from depression or symptoms similar to depression”. Furthermore, we also wanted to 
control for participant’s prior beliefs around trade-off between greater effectiveness and 
increased severity of side effects. Tradeoff was measured with the item: “FDA's GmbH medical 
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index provides effectiveness rating of the drug on a 0 to 100 scale, with 100 being most effective. 
If a drug is ranked as 100 percent effective on this index, what would be your estimate of the 
extent to which this drug would have serious side-effects”.  It is important to note that although 
increased side-effects with dose-related increases in efficacy (benefits) can sometimes occur for 
a specific medicine, in many cases there is no clear link between likelihood of benefit and harm.  
Study 2a. Participants. Four hundred US participants, the typical audience for DTC 
advertisements, were recruited using AMT (Mage=35.69; 45.75% female; response rate 93.7%). 
As print advertisements are lower on media richness
25
, we felt a smaller sample size would 
suffice, but still recruited a large enough sample (≈200 per cell) to avoid any possibility of Type-
1 error. Study 1 participants were excluded from partaking in Study 2a. 
Design and Procedure. Participants were shown an actual print advertisement for the drug 
Lunesta, designed to treat sleep disorder (see Figure S1 and Figure S2 in the Supplemental 
Materials available online for the drug ad). Randomly assigned participants either read the 
complete set of 4 side effects (2 major and 2 minor) – complete side effects condition (n=200) – 
or a subset of 2 major side effects – major side effects condition (n=200). The 2 major side 
effects were uncontrollable shaking of a body part and mental problems with attention. The 2 
minor side effects included in the complete side effects condition were dry mouth and headache. 
Participants then rated the severity of side effects and attractiveness of Lunesta, similar to Study 
1. Participants also rated their perceptions of tradeoff and their own susceptibility to sleep 
disorder, using the identical items from Study 1. 
Study 2b. Participants. Similar to Study 2a, we set out to recruit approximately 200 participants 
per cell. Our final sample consisted of 399 participants from AMT (Mage=38.48; 55.64% female; 
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response rate 92.58%). Participants from prior studies were excluded from partaking in this 
study. 
Design and Procedure. Participants were shown a Drug Facts Box for the drug Abilify, 
manufactured to treat depression. The Drug Facts Box employed was identical to the one used 
and prescribed by Schwartz and Woloshin
19
. Randomly assigned participants either read the 
complete information about the drug– complete side effects condition (n=196) – or the complete 
information excluding few minor side effects – major side effects condition (n=203). Participants 
then rated the severity and attractiveness of Abilify, similar to the above studies.  
Study 2c. Participants. Given the similar medium of print to studies 2a and 2b, we once again 
aimed to recruit approximately 200 participants per cell. Our final sample consisted of 452 
participants from AMT (Mage=37.63; 56.42% female; response rate 90.6%). As before, 
participants who took part in prior similar studies were excluded from partaking in this study. 
Design and Procedure. Participants were presented with the text from an advertisement for the 
Attention Deficit Hyperactive Disorder (ADHD) drug – Concerta –, whose side effects were 
sandwiched in between the benefits and merits of the drug. This manipulation squarely mirrored 
the architecture employed by several drug commercials where both the beginning and conclusion 
of the advertisement is devoted to highlighting various strengths or benefits associated with the 
drug with the side effects inserted in between. Randomly assigned participants either read the 
complete side effects of the drug including both major and minor– complete side effects 
condition (n=225) – or all major side effects barring the minor side effects – major side effects 
condition (n=227). Participants then rated the severity and attractiveness of Abilify, similar to the 
above studies. In previous studies drug severity was measured using items evaluating the 
seriousness, harm or risk associated with the drug. However, in this study we included an 
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additional item employing a different frame. Specifically, participants responded to the item 
“how safe would it be to consume Concerta” (=.81). Finally, participants reported if they were 
suffering from ADHD and their perceptions of trade-off.    
Study 3. Participants. Consistent with our rationale for sample size and similar to Studies 2a-c 
using a text based stimuli, we recruited roughly 200 US participants per cell (N= 604; 
Mage=34.97; 45.70% female; response rate 92.4%). As before, participants who took part in prior 
similar studies were excluded from partaking in this study. 
Design and Procedure. To strip away the extraneous information typically found in actual drug 
commercials that may crowd out viewer’s attention to side effects, Study 3 only provided 
participants with information about side effects. Participants read about a hypothetical drug, 
Xylopinol, which treats sleep disorder. This was a 3-condition between-subject design, whereby 
participants were randomly assigned to a major, or a complete or a complete –major side effect 
emphasized condition. In the major side effects condition, they were informed of only four major 
side effects of a hypothetical drug, Xylopinol, designed to aid insomnia, whereas in the complete 
side effects condition, they were alerted to both four major and two minor side effects. In the 
complete major side effects emphasized condition, participants read about both major and minor 
side effects, with major side effects more emphasized compared to the minor ones. Participants 
read that several pharmaceutical companies were actively working to develop drugs that could be 
effective in treating these sleep disorders. Following this, participants were either informed of 
the four major side effects (memory loss, depression, severe liver issues and suicidal thoughts), 
both the four major and two minor side effects (headache and dry mouth) or the complete side 
effects emphasized condition. Specifically, they read:  
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One such company, Astrazin Pharmaceutical Ltd., has developed a drug, Xylopinol that 
treats sleep disorders. US Food and Drug Administration (FDA) has found the drug to be 
effective and have approved the drug for sale in the United States. 
However, as is the case with most drugs, Xylopinol may result in some unwanted side 
effects such as memory loss, depression, severe liver issues and suicidal thoughts (, 
headache and dry mouth). 
After reading the scenario, all participants responded to a set of questions identical to Studies 2a 
and 2b aimed at assessing severity of side effects and drug attractiveness. Identical to Study 1 
and Studies 2a-c, participants also rated their perception of quality, prior belief of tradeoff and 
their own susceptibility to sleep disorder. 
Statistical Analysis. All analyses were performed using the statistical software Stata. Data 
across conditions were analyzed using a one-way analysis of variance with post hoc analysis of 
means. Testing of indirect effect was carried out using bootstrap procedure with 5000 iterations. 
Significance was assumed for p values less than .05.  
Data availability. The authors declare that all data supporting the findings, study protocols and 
stimulus materials are available at https://osf.io/yw47v/.  
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Table 1: Descriptive summary of results with means and standard deviation in parentheses. 
 
 
 
 
 
Note. Each cell in the row denoted by severity of side effects represents mean value followed by standard deviation in parentheses. 
 
  
 
Study 1 Study 2a Study 2b Study 2c Study 3 
 
Full audio 
Partial 
audio 
Complete 
side effects 
Major side 
effects 
 
Complete 
side effects 
 
Major 
side 
effects 
 
Complete 
side effects 
 
Major side 
effects 
 
Complete 
side effects 
Major 
side 
effects 
Complete-major 
side effects 
emphasized 
N 398 406 200 200 196 203 225 227 201 199 204 
Severity of side 
effects 
5.43 (1.08) 5.62 (1.15) 4.09 (1.27) 4.41 (1.27) 5.33 (1.22) 5.74 (.98) 5.13 (1.16) 5.47 (1.10) 5.52 (1.12) 5.85 (.88) 5.84 (.88) 
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Table 2: Separate one way ANOVA analysis for each of the four different items measuring overall drug severity across complete 
and major side effects condition. Effects are significant and consistent for each of the item across all five studies  
 How serious are drug’s side effects How harmful are drug’s side 
effects 
How would you assess the overall 
risk factor of using this drug? 
How safe would it be to consume this 
drug? 
 Complete 
side 
effects 
Major 
side 
effects  
Probability 
(difference 
in means) 
Complete 
side 
effects  
Major 
side 
effects  
Probability 
(difference 
in means) 
Complete 
side 
effects  
Major 
side 
effects  
Probability 
(difference 
in means) 
Complete 
side 
effects  
Major side 
effects  
Probability 
(difference 
in means) 
             
Study 1 5.49 
(1.12) 
5.66 
(1.18) 
0.039 5.37 
(1.15) 
5.57 
(1.22) 
0.016       
Study 2a 4.25 
(1.38) 
4.59 
(1.36) 
0.012    3.92 
(1.34) 
4.22 
(1.34) 
0.025    
Study 2b 5.43 
(1.27) 
5.89 
(1.01) 
0.0001    5.23 
(1.33) 
5.60 
(1.13) 
0.003    
Study 2c 5.67 
(1.29) 
6.05 
(1.06) 
0.001    5.19 
(1.34) 
5.50 
(1.30) 
0.013 3.47  
(1.5) 
3.14 
(1.46) 
0.019 
Study 3 5.75 
(1.16) 
6.11  
(.87) 
0.001    5.29 
(1.24) 
5.60 
(1.06) 
0.001    
 
Note. Each cell (except ones under the probability column) denotes mean values followed by standard deviation in parentheses.  
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Figure 1: The interaction effect of the two audio conditions and participants’ recall of major side effects on drug’s overall severity 
(N=804). Slope for only partial audio condition is significant (p<.05). 
